Meet The Team
Jenna Baker, PhD
Co-Founder & CEO
A broadly trained scientist with research across multiple disciplines, Jenna brings more than 20 years of life science experience in the academic, private, and government sectors to Gypsy Basin Genomics. By combining her background in computational and functional genomics with her leadership experience, she is helping GBG translate clinically relevant genomic signatures into advances in personalized clinical care.
Chief Business Officer
As the Chief Business Officer for Gypsy Basin Genomics, Anne brings over 30 years of managerial, financial, and accounting experience to GBG, most recently as Vice President, Finance and Administration at Catalent Pharma Solutions (formerly Paragon Bioservices, Inc.) where she was instrumental in the sale of Paragon to Catalent in May 2019. She has expertise in leading the start-up and rapid growth of new and emerging companies.
Joe brings over 25 years of global healthcare experience in oncology, infectious disease, and respiratory therapeutic areas. He led the introduction for Merck of the first HPV vaccine, Gardasil, and was responsible for the formation of numerous global research, commercial, & manufacturing partnerships. He is recognized for his many successes commercializing technologies and building new product markets.
Anna Giuliano, PhD
HPV Scientific Advisor
Dr. Giuliano is the Founding Director of the Center for Immunization and Infection Research in Cancer (CIIRC) at the Moffitt Cancer Center. Her work has contributed significantly to our understanding of the rate at which HPV infections are acquired and cleared, the proportion that progress to disease, and also to HPV vaccine protection against multiple diseases in women and men.
Senior Strategy Advisor
David is a seasoned healthcare CEO and Combat Veteran with over 20 years of experience commercializing diagnostics. He has built and scaled multiple healthcare companies that resulted in successful exits to strategic buyers. He was the CEO at Armune BioScience, which sold to Exact Sciences [EXAS] in Dec. 2017, as well as the US President at Phadia US/AB, which sold to Thermo Fisher Scientific [TMO] Sept. 2011).
Lynn has been the President and CEO of the American Sexual Health Association and the National Cervical Cancer Coalition since 2006, advocating for HPV
vaccination and testing. She works closely with colleague organizations, from the American Sexual Transmitted Diseases Association, the National Coalition of STD Directors, and the Centers for Disease Control and Prevention.